New drug combo shows promise for tough-to-treat lymphoma
NCT ID NCT04214626
First seen Nov 19, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study tested whether adding lenalidomide to standard chemotherapy (R-CHOP) could improve outcomes for people with a fast-growing type of lymphoma called diffuse large B-cell lymphoma. The trial included 60 patients with medium-to-high risk disease who had not yet received treatment. Researchers measured how many patients remained cancer-free after two years and tracked side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.